We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: anlotinib
MedXY News
EnglishTag

anlotinib

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma
newsanlotinibchemotherapy

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma

By MedXY|Jan 20, 2026

This Phase II trial evaluates first-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance for advanced soft-tissue sarcoma, showing an objective response rate of 30.8% and a manageable safety profile, suggestin

Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC
newsanlotinibneoadjuvant therapy

Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC

By MedXY|Jan 19, 2026

The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para

Clinical UpdatesanlotinibKRAS mutation

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY|Oct 8, 2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities